Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro

• Published in: Journal of thoracic oncology Vol. 14; no. 10; pp. 1753 - 1765
• Main Authors: Fujino, Toshio, Kobayashi, Yoshihisa, Suda, Kenichi, Koga, Takamasa, Nishino, Masaya, Ohara, Shuta, Chiba, Masato, Shimoji, Masaki, Tomizawa, Kenji, Takemoto, Toshiki, Mitsudomi, Tetsuya
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2019; Copyright by the International Association for the Study of Lung Cancer
• Subjects: Drug resistance; Lung cancer; MET proto-oncogene; Mutation; Receptor tyrosine kinase; Receptor tyrosine kinase; MET proto-oncogene; Mutation; Drug resistance; Lung cancer
• ISSN: 1556-0864; 1556-1380
• DOI: 10.1016/j.jtho.2019.06.023

MNNG HOS transforming gene (MET) exon 14 mutations in lung cancer, including exon 14 skipping and point mutations, have been attracting the attention of thoracic oncologists as new therapeutic targets. Tumors with these mutations almost always acquire resistance, which also occurs in other oncogene-addicted lung cancers. However, the resistance mechanisms and treatment strategies are not fully understood. We generated Ba/F3 cells expressing MET exon 14 mutations by retroviral gene transfer. The sensitivities of these cells to eight MET-tyrosine kinase inhibitors (TKIs) were determined using a colorimetric assay. In addition, using N-ethyl-N-nitrosourea mutagenesis, we generated resistant clones, searched for secondary MET mutations, and then examined the sensitivities of these resistant cells to different TKIs. Ba/F3 cells transfected with MET mutations grew in the absence of interleukin-3, indicating their oncogenic activity. These cells were sensitive to all MET-TKIs except tivantinib. We identified a variety of secondary mutations. D1228 and Y1230 were common sites for resistance mutations for type I TKIs, which bind the active form of MET, whereas L1195 and F1200 were common sites for type II TKIs, which bind the inactive form. In general, resistance mutations against type I were sensitive to type II, and vice versa. MET-TKIs inhibited the growth of cells with MET exon 14 mutations. We also identified mutation sites specific for TKI types as resistance mechanisms and complementary activities between type I and type II inhibitors against those mutations. These finding should provide relevant clinical implication for treating patients with lung cancer harboring MET exon 14 mutations.